Drug Trials Snapshots: IMJUDO (tremelimimab-actl)

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-imjudo IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma.